| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | 0.066 | 0.6 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |